Immunotherapy for Cat Allergy by Injecting Allergen into the Lymph Node: Safety and Effects on the Immune System
Descrizione riassuntiva dello studio
Cat (hair) allergies are often difficult to treat and significantly affect those affected, as the allergens are hard to avoid. The only approved way to treat the allergy itself is currently subcutaneous immunotherapy. In this treatment, patients are "desensitized" to the allergen by injecting it under the skin in a low, gradually increasing dose. However, individuals with cat allergies often experience side effects during this treatment. A form of immunotherapy that has only been studied so far is called intralymphatic immunotherapy, where the allergen is injected directly into a lymph node under ultrasound control. This directly targets certain immune system cells. Fewer injections are needed compared to subcutaneous immunotherapy, and fewer side effects are expected. This therapy has already been applied in studies with various allergens and showed positive results, although it has been tested on relatively few patients so far. In this study, we aim to investigate whether intralymphatic immunotherapy is well tolerated and safe for cat allergy and whether it shows effects on cat allergy. In the first phase of the study, a well-tolerated and safe dose for the therapy will be determined, and in the second phase, the therapy will be conducted in three different treatment groups. These differ in the dosage of intralymphatic immunotherapy. The treatment will last for three months, followed by a follow-up phase of another three months.
(BASEC)
Intervento studiato
Intralymphatic immunotherapy (immunotherapy by injecting the allergen into the lymph node)
(BASEC)
Malattie studiate
Cat (hair) allergy
(BASEC)
Cat allergy (BASEC)
Criteri di esclusione
severe, uncontrolled asthma pregnancy chronic inflammatory or malignant diseases (BASEC)
Luogo dello studio
Zurigo
(BASEC)
Sponsor
Professor Pål Johansen, Universitätsspital Zürich
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
ILIT-Studienteam (Claudia Lang, Alexandra Steiger)
+41 (0)43 253 7855
ilit-studie@clutterusz.chDermatologische Klinik, Universitätsspital Zürich
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione etica Zurigo
(BASEC)
Data di approvazione del comitato etico
16.05.2025
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
Safety and immunogenicity of cat-allergen intralymphatic immunotherapy: an open label Phase II study in patients with cat allergy with and without asthma (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile